Provided by Tiger Trade Technology Pte. Ltd.

Ascendis Pharma A/S

231.94
-32.9819-12.45%
Volume:1.24M
Turnover:292.41M
Market Cap:15.35B
PE:17.90
High:257.53
Open:256.25
Low:228.56
Close:264.92
52wk High:282.15
52wk Low:186.05
Shares:66.19M
Float Shares:65.54M
Volume Ratio:6.25
T/O Rate:1.89%
Dividend:- -
Dividend Rate:- -
EPS(TTM):12.96
EPS(LYR):-4.4176
ROE:118.78%
ROA:9.58%
PB:9.26
PE(LYR):-52.50

Loading ...

Ascendis Pharma A/S expected to post earnings of 20 cents a share - Earnings Preview

Reuters
·
May 05

Ascendis Pharma updates financial calendar with upcoming first-quarter results call

Reuters
·
May 01

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Apr 30

Assessing Ascendis Pharma (ASND) Valuation After Recent Share Price Uptick And Ongoing Losses

Simply Wall St.
·
Apr 27

Ascendis Pharma A/S expected to post earnings of 28 cents a share - Earnings Preview

Reuters
·
Apr 27

Ascendis Pharma to Redeem Senior Notes due 2028

MT Newswires Live
·
Apr 22

Ascendis Pharma calls USD 575 million convertible notes for redemption May 6

Reuters
·
Apr 22

European Equities Traded in the US as American Depositary Receipts Sharply Lower in Tuesday Trading

MT Newswires Live
·
Apr 21

Ascendis Pharma updates ISIN for Nasdaq Global Select Market-listed shares

Reuters
·
Apr 21

Ascendis Pharma ordinary shares begin trading on Nasdaq, replacing ADS listing

Reuters
·
Apr 20

Ascendis Pharma Is Maintained at Buy by B of A Securities

Dow Jones
·
Apr 16

Analysts Offer Insights on Healthcare Companies: Ascendis Pharma (ASND) and Concentra Group Holdings Parent, Inc. (CON)

TIPRANKS
·
Apr 16

Ascendis Pharma Share Conversion Reshapes Access And Liquidity On Nasdaq

Simply Wall St.
·
Apr 15

European Equities Traded in the US as ADRs Rise in Tuesday Trading

MT Newswires Live
·
Apr 14

How Investors May Respond To Ascendis Pharma (ASND) Achondroplasia Combo Data And YUVIWEL Launch

Simply Wall St.
·
Apr 11

European Equities Traded in the US as American Depositary Receipts Decline in Thursday Trading

MT Newswires Live
·
Apr 09

Ascendis Pharma Price Target Maintained With a $273.00/Share by Wedbush

Dow Jones
·
Apr 09

Wedbush Reaffirms Their Buy Rating on Ascendis Pharma (ASND)

TIPRANKS
·
Apr 09

Ascendis Pharma to list ordinary shares directly on Nasdaq from April 20

Reuters
·
Apr 09

Ascendis Pharma announces new data from COACH trial

TIPRANKS
·
Apr 08